Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis

Gustav Hjort,Christopher Willy Schwarz,Lone Skov,Nikolai Loft

DOI: https://doi.org/10.1001/jamadermatol.2024.1677

IF: 11.816

2024-08-23

JAMA Dermatology

Abstract:This meta-analysis examines the association between clinical characteristics and the clinical response among patients with psoriasis treated with biologics.

dermatology

What problem does this paper attempt to address?

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study

Christopher Willy Schwarz,Nikolai Loft,Mads Kirchheiner Rasmussen,Christoffer V. Nissen,Tomas Norman Dam,Kawa Khaled Ajgeiy,Alexander Egeberg,Lone Skov

DOI: https://doi.org/10.2340/actadv.v101.351

2021-10-26

Acta Dermato Venereologica

Abstract:Identifying patient characteristics associated withachieving treatment response to biologics in patients with psoriasis could prevent expensive switching between biologics. The aim of this study was to identifypatient characteristics that predict the efficacy of treatment for biologics that inhibit tumour necrosis factor-α, interleukin-12/-23, and -17A. The study investigated biologic-naïve patients from the DERMBIO registry treated with adalimumab, etanercept, infliximab, secukinumab, or ustekinumab. Multivariable logistic models were conducted to assess associations between patient characteristics and treatment response. A total of 2,384 patients were included (adalimumab n = 911; etanercept n = 327; infliximab n = 152; secukinumab n = 323; ustekinumab n = 671). Smoking (odds ratio 0.74; 95% confidence interval (CI) 0.56–0.97; p = 0.03) and higher bodyweight (odds ratio 0.989; 95% CI 0.984–0.994; p < 0.001) reduced the odds of achieving response defined as Psoriasis Area and Severity Index ≤2.0 after 6 months of treatment. In conclusion, higher bodyweight and smoking were associated with a reduced probability of treatment response for tumour necrosis factor-α inhibitors, ustekinumab, and secukinumab.

dermatology
Characteristics of Patients With Psoriasis Treated With Various Biologics - A Danish Cohort Study

Christopher Willy Schwarz,Lone Skov,Alexander Egeberg,Alun Passey,Jennifer Lee,Patricia Gorecki,Nikolai Loft

DOI: https://doi.org/10.1177/24755303241234292

Abstract:Background: Psoriasis is associated with several comorbidities and patients with psoriasis are more often obese than individuals without psoriasis. The excess disease burden is important to consider in choice of and response to treatment at the individual level. Objective: To investigate whether patient characteristics differ across biologics for patients initiating biologic therapy and for patients still on biologic therapy after 1 year. Also, to quantify and compare the use of topical therapy among patients still on biologic therapy after 1 year. Methods: This nationwide cohort study compared characteristics of patients prescribed adalimumab, etanercept, infliximab, secukinumab or ustekinumab for treatment of psoriasis by using data from the Danish registries. Results: In the ustekinumab group, patients were younger and fewer had psoriatic arthritis. Patients treated with secukinumab and ustekinumab were less frequently co-treated with conventional systemics and topical therapy. All other patient characteristics such as sex, smoking and comorbidities other than psoriatic arthritis were similar across the biologic cohorts. Conclusion: These results highlight the need to better understand which factors to consider when prescribing biologics to patients with psoriasis.
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials

Alexander Egeberg,Curdin Conrad,Patricia Gorecki,Sven Wegner,Jozefien Buyze,Lorenzo Acciarri,Diamant Thaçi

DOI: https://doi.org/10.1007/s13555-024-01123-1

2024-03-16

Dermatology and Therapy

Abstract:This study aimed to understand treatment response dynamics, including factors associated with favorable response, among patients with moderate-to-severe psoriasis who received guselkumab, adalimumab, or secukinumab.

dermatology
Mechanisms in residual plaques in patients with an overall good response to biologics

K. M. Smith,S. Mashiko,R. Edelmayer,Y. Bi,V. Kaimal,L. Olson,S. Huang,J. Wetter,K. Salte,J. Wang,X. Li,S. Garcet,A. Kannan,S. Cao,C. Maari,E. St-Cyr Proulx,Z. Liu,J. Krueger,M. Sarfati,R. Bissonnette

DOI: https://doi.org/10.1016/j.jid.2018.03.491

IF: 7.59

2018-01-01

Journal of Investigative Dermatology

Abstract:The majority of psoriasis patients treated with biologics respond with 75-90% skin clearance. These patients possess “residual plaques” which can cover 1-5% of body surface area. To elucidate mechanisms of plaque persistence despite overall good response to drug, we studied fifty subjects: psoriasis patients treated with three different biologics with refractory plaques, untreated patients, and healthy controls. All subjects had skin biopsies collected. Biopsies were characterized using three methods: mRNA gene expression, histology, and FACS of isolated hematopoietic cells. Gene expression analysis revealed persistence of key psoriasis pathways in residual plaques, in spite of evidence of drug effects. Active pathways include “Granulocyte Adhesion and Diapedesis”, “Role of IL-17A in Psoriasis”, and “Interferon Signaling”. All data types showed some dampening of immune mediators by biologic therapy. Focal decreases in parakeratosis and keratinocyte proliferation in treated plaques consistent with a partial drug effect were observed histologically. Single cell analysis showed differential reduction in IL-17 producing CD103- T cells and increase in mast cells producing IL-22 while frequency of CD103+ T cells remained unchanged, providing further evidence of drug effect. Our hypothesis is that high inflammatory burden persists in refractory plaques and standard doses of therapy are inadequate to induce clinical resolution.
HLA‐C*06:02 in Danish patients with psoriasis and response to biological treatment

Mie Siewertsen Bergmann,Nikolai Loft,Christopher Willy Schwarz,Diljit Kaur‐Knudsen,Claus Zachariae,Lone Skov

DOI: https://doi.org/10.1111/1346-8138.17415

IF: 3.468

2024-08-29

The Journal of Dermatology

Abstract:Whether clinical and genetic markers can be used to differentiate patients with varying responses to different psoriasis therapies needs to be elucidated. Here, we assess whether human leukocyte antigen C (HLA‐C)*06:02 is associated with response to biologics. Response to treatment was defined as a Psoriasis Area and Severity Index score of ≤2 (PASI≤ 2) after 3 months. In total, 648 patients with psoriasis initiating treatment with biologics were included; 289 were HLA‐C*06:02 positive and 359 were HLA‐C*06:02 negative. Patients were treated with tumor necrosis factor (TNF) inhibitors (n = 469), interleukin (IL)‐12/23 inhibitors (n = 92), IL‐17 inhibitors (n = 78), and IL‐23 inhibitors (n = 9). Significantly more patients positive for HLA‐C*06:02 achieved PASI≤ 2 compared with patients negative for HLA‐C*06:02 when treated with IL‐12/23 inhibitors. There was no significant difference between response in HLA‐C*06:02 positive and negative patients for TNF inhibitors or IL‐17 inhibitors. No analyses were conducted for IL‐23 inhibitors because of the limited number of patients. The data confirm that HLA‐C*06:02 may be used as a biomarker for response to anti‐IL12/23 treatment.

dermatology
Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)

April W Armstrong,Elisabeth Riedl,Patrick M Brunner,Stefano Piaserico,Willie I Visser,Natalie Haustrup,Bruce W Konicek,Zbigniew Kadziola,Mercedes Nunez,Alan Brnabic,Christopher Schuster

DOI: https://doi.org/10.2340/actadv.v104.40556

2024-09-05

Abstract:Despite the abundance of data concerning biologic treatments for patients with psoriasis, clinicians are often challenged with discerning the optimal treatment for each patient. To inform this selection, this study explored whether a patient's baseline characteristics or disease profile could predict the likelihood of achieving complete skin clearance with biologic treatment. Machine-learning and other statistical methods were applied to the substantial data collected from patients with moderate-to-severe psoriasis in the ongoing, international, prospective, observational Psoriasis Study of Health Outcomes (PSoHO). The 3 measures of complete skin clearance were a psoriasis area and severity index (PASI)100 response at (a) week 12, (b) month 12, and (c) week 12 and maintain ed at month 6 and month 12 (PASI100 durability). From these real-world data, the absence of nail psoriasis emerged as the most consistent feature that may be used by clinicians to predict high-level treatment responses with biologic treatment. Other significant predictors of skin clearance with biologic treatments were the absence of hypertension and a lower body surface area affected by psoriasis. Overall, this study evidences the substantial challenge of identifying reliable clinical markers of treatment response for patients with psoriasis and highlights the importance of regular screening for psoriatic nail involvement.
Chinese Experts Consensus on Biologic Therapy for Psoriasis #

Chinese Society of Dermatology,China Dermatologist Association,Dermatology and Venereology Specialized Committee of Chinese Association of Integrative Medicine,Chen Ai-Jun,Gao Xing-Hua,Gu Heng,Gu Jun,Hao Fei,Jiang Xian,Jin Hong-Zhong,Kang Xiao-Jing,Li Cheng-Xin,Li Yu-Zhen,Liu Xiao-Ming,Shi Yu-Ling,Sun Qing,Wang Gang,Yang Bin,Zhang Jun-Ling,Zhang Xi-Bao,Zhang Xue-Jun,Zhao Yi,Zheng Min

DOI: https://doi.org/10.1097/jd9.0000000000000079

2020-01-01

International Journal of Dermatology and Venereology

Abstract:Abstract. Biologic drugs have been increasingly used in the treatment of psoriasis and are especially favorable for severe, recalcitrant, and special-type cases. Therefore, appropriate, effective, and safe use of biologic drugs has drawn attention from dermatologists. For this purpose, Chinese experts majoring in psoriasis analyzed domestic and international research data, summarized current clinical experiences, investigated features of Chinese patients with psoriasis, and finally formulated the present consensus, which provides detailed guidances to clinicians in terms of the principles and methods of the application of biologics, the efficacy and safety profile, patient screening and monitoring, main adverse events and corresponding solutions, and precautions for special patient populations.
Biomarkers of systemic treatment response in people with psoriasis: a scoping review

Mark Corbett,Ravi Ramessur,David Marshall,Marcio L Acencio,Marek Ostaszewski,Ines A Barbosa,Nick Dand,Paola Di Meglio,Salma Haddad,Andreas H M Jensen,Witte Koopmann,Satveer K Mahil,Seher Rahmatulla,Joe Rastrick,Jake Saklatvala,Stephan Weidinger,Kath Wright,Kilian Eyerich,Jonathan N Barker,Matladi Ndlovu,Curdin Conrad,Lone Skov,Catherine H Smith,BIOMAP consortium

DOI: https://doi.org/10.1111/bjd.21677

Abstract:Background: Responses to the systemic treatments commonly used to treat psoriasis vary. Biomarkers that accurately predict effectiveness and safety would enable targeted treatment selection, improved patient outcomes and more cost-effective healthcare. Objectives: To perform a scoping review to identify and catalogue candidate biomarkers of systemic treatment response in psoriasis for the translational research community. Methods: A systematic search of CENTRAL, Embase, LILACS and MEDLINE was performed for relevant articles published between 1990 and December 2021. Eligibility criteria were studies involving patients with psoriasis (any age, n ≥ 50) reporting biomarkers associated with systemic treatment response. The main outcomes were any measure of systemic treatment efficacy or safety. Data were extracted by one reviewer and checked by a second; studies meeting minimal quality criteria (use of methods to control for confounding) were formally assessed for bias. Candidate biomarkers were identified by an expert multistakeholder group using a majority voting consensus exercise and mapped to relevant cellular and molecular pathways. Results: Of 71 included studies (67 studying effectiveness outcomes and eight safety outcomes; four studied both), most reported genomic or proteomic biomarkers associated with response to biologics (48 studies). Methodological or reporting limitations frequently compromised the interpretation of findings, including inadequate control for key covariates, lack of adjustment for multiple testing, and selective outcome reporting. We identified candidate biomarkers of efficacy to tumour necrosis factor inhibitors [variation in CARD14, CDKAL1, IL1B, IL12B and IL17RA loci, and lipopolysaccharide-induced phosphorylation of nuclear factor (NF)-κB in type 2 dendritic cells] and ustekinumab (HLA-C*06:02 and variation in an IL1B locus). None were supported by sufficient evidence for clinical use without further validation studies. Candidate biomarkers were found to be involved in the immune cellular crosstalk implicated in psoriasis pathogenesis, most notably antigen presentation, T helper (Th)17 cell differentiation, positive regulation of NF-κB, and Th17 cell activation. Conclusions: This comprehensive catalogue provides a key resource for researchers and reveals a diverse range of biomarker types and outcomes in the included studies. The candidate biomarkers identified require further evaluation in methodologically robust studies to establish potential clinical utility. Future studies should aim to address the common methodological limitations highlighted in this review to expedite discovery and validation of biomarkers for clinical use. What is already known about this topic? Responses to the systemic treatments commonly used to treat psoriasis vary. Biomarkers that accurately predict effectiveness and safety would enable targeted treatment selection, improved patient outcomes and more cost-effective healthcare. What does this study add? This review provides a comprehensive catalogue of investigated biomarkers of systemic treatment response in psoriasis. A diverse range of biomarker types and outcomes was found in the included studies, serving as a key resource for the translational research community.
The impacts of biologic treatment on metabolic profiling in psoriasis

Sichun Deng,Guowei Zhou,Xingyu Li,Guanxiong Zhang,Kun Hu,Yan Lu,Jiashuai Li,Yijie Liu,Guo Zhou,Mi Zhang,Junchen Chen,Hong Liu,Yehong Kuang

DOI: https://doi.org/10.1111/exd.15011

2024-01-19

Experimental Dermatology

Abstract:Psoriasis is an immune‐mediated inflammatory disease commonly accompanied by various metabolic disorders. It is widely known that biologics could affect the metabolic status and comorbidities in psoriasis patients, however, the effects of biologics on metabolism in psoriasis patients remain poorly understood. The aim of this study was to elucidate the characteristic changes of metabolic profiling in psoriasis vulgaris (PsV) patients before and after applying biologics. Plasma samples were collected from a retrospective cohort of 43 PsV patients. Non‐targeted metabolomics analyses were performed using liquid chromatography‐mass spectrometry (LC–MS) to compare the metabolic profiles before and after applying adalimumab (ADA) or ixekizumab (IXE) for 4 weeks. Additionally, correlation analyses were conducted to investigate the associations between metabolite expression levels and clinical characteristics. The biologics significantly affected the metabolic profiles of PsV patients especially in glycerophospholipids (GPs). First, phosphatidylcholine (PC), unsaturated lysophosphatidylcholine (LPC), unsaturated lysophosphatidic acid (LPA) and unsaturated lysophosphatidylethanolamine (LPE) were significantly up‐regulated, whereas phosphatidylethanolamine (PE), saturated LPC, saturated LPA and saturated LPE were predominantly down‐regulated after biologic treatment. What is more, the changes in PE and LPA were mainly observed after applying IXE instead of ADA. Second, we also found GPs including PC, unsaturated LPC, unsaturated LPA and unsaturated LPE were primarily negatively correlated with disease severity, whereas, PE, saturated LPC, saturated LPA and saturated LPE displayed inverse correlations. Biologics could affect GP metabolism and facilitate the transition of metabolic status from a pro‐inflammatory to an anti‐inflammatory phenotype in PsV patients.

dermatology
Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis

Weiqi Gao,Boran Yu,Ya Yan,Libo Zhao,Rongsheng Zhao

DOI: https://doi.org/10.3389/fimmu.2023.1151977

2023-05-25

Abstract:Introduction: Biologics is used for treating moderate to severe plaque psoriasis (MSPP), which represent one of the foremost therapeutic advancements in disease of dermatology. Up to now, the relative efficacy and safety across approved andinvestigational biologics for MSPP is still unclear. Methods: This study aimed to comparative effectiveness of various biological treatments for MSPP measured by PASI75, PASI90 and PASI100 (The ratio of patients whose Psoriasis Area and Severity Index score (PASI) decreased by ≥ 75%, 90% and 100% compared with baseline, respectively). In addition, random models were used together with a Bayesian method to compare direct and indirect Adverse Events (AEs) of biologics with placebo, to make probabilistic statements and predictions on their AEs. The analytic data set was made up of summarized data from 54 trials, including 27,808 patients, with treatment of 17 biologics. Three mathematic models with nonparametric placebo evaluations were established to characterize the longitudinal direction profile for the three efficacy measures as above mentioned. Results: Our results showed significant differences among treatments. Bimekizumab, sonelokimab, and ixekizumab were found to be the most effective treatments among the biologics. The effects of covariate were further evaluated, patients' age, body weight, duration of disease and percentage of patients previously treated with a biological therapy showed impact on the efficacy. In addition, we found that ixekizumab and risankizumab displayed relatively stable as for efficacy and safety. Discussion: Our findings provide valuable insights into the comparative effectiveness and safety of biologics for MSPP treatment. These results may aid in clinical decision-making and ultimately improve patient outcomes.
Association between several immune response‐related genes and the effectiveness of biological treatments in patients with moderate‐to‐severe psoriasis

Alba Loras,Marta Gil‐Barrachina,Barbara Hernando,Gemma Perez‐Pastor,Alvaro Martinez‐Domenech,Laura Mahiques,Gerard Pitarch,Francisca Valcuende‐Cavero,Rosa Ballester‐Sanchez,Maria Angeles Marques‐Torrejon,Conrado Martinez‐Cadenas

DOI: https://doi.org/10.1111/exd.15003

2024-01-05

Experimental Dermatology

Abstract:Biological therapies are safer and more effective against psoriasis than conventional treatments. Even so, 30–50% of psoriatic patients show an inadequate response, which is associated with individual genetic heterogeneity. Pharmacogenetic studies have identified several single nucleotide polymorphisms (SNPs) as possible predictive and prognostic biomarkers for psoriasis treatment response. The objective of this study was to determine the link between several SNPs and the clinical response to biological therapies in patients with moderate–severe psoriasis. A set of 21 SNPs related to psoriasis and/or other immunological diseases were selected and analysed from salivary samples of patients (n = 88). Treatment effectiveness and patient improvement was assessed clinically through Relative Psoriasis Area and Severity Index (PASI), also called 'PASI response', as well as absolute PASI. Associations between SNPs and PASI factors were assessed at 3 and 12 months for every treatment category of IL‐17, IL‐23, IL‐12&23 and TNF‐α inhibitors. Multivariate correlation analysis and Fisher's exact test were used to analyse the relationship between SNPs and therapy outcomes. Several SNPs located in the TLR2, TLR5, TIRAP, HLA‐C, IL12B, SLC12A8, TNFAIP3 and PGLYRP4 genes demonstrated association with increased short and long‐term therapy‐effectiveness rates. Most patients achieved values of PASI response ≥75 or absolute PASI<1, regardless of the biological treatment administered. In conclusion, we demonstrate a relationship between different SNPs and both short‐ and especially long‐term effectiveness of biological treatment in terms of PASI. These polymorphisms may be used as predictive markers of treatment response in patients with moderate‐to‐severe psoriasis, providing personalized treatment.

dermatology
Early Clinical Response As A Predictor of Subsequent Response to Ixekizumab Treatment: Results from A Phase Ii Study of Patients with Moderate-To-Severe Plaque Psoriasis

B. Zhu,E. Edson-Heredia,G. S. Cameron,W. Shen,J. Erickson,D. Shrom,P. Wang,S. Banerjee,K. B. Gordon

DOI: https://doi.org/10.1111/bjd.12610

2013-01-01

Abstract:Early identification of responsiveness to biologic treatments in psoriasis has significant clinical and economic implications.
Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004–2022

Thomas Graier,Wolfgang Salmhofer,Constanze Jonak,Wolfgang Weger,Claudia Zikeli,Barbara Gruber,Paul Sator,Knut Prillinger,Alexander Mlynek,Martina Schütz‐Bergmayr,Leo Richter,Gudrun Ratzinger,Christoph Sassmann,Clemens Painsi,Nina Häring,Katharina Wippel‐Slupetzky,Hans Skvara,Hannes Trattner,Martin Inzinger,Christina Bangert,Christina Ellersdorfer,Katharina Falkensteiner,Birgit Sadoghi,Alexandra Gruber‐Wackernagel,Angelika Hofer,Franz Legat,Bernhard Lange‐Asschenfeldt,Matthias Schmuth,Igor Vujic,Wolfram Hötzenecker,Werner Saxinger,Robert Müllegger,Franz Quehenberger,Peter Wolf

DOI: https://doi.org/10.1111/ddg.15213

2023-11-02

JDDG - Journal of the German Society of Dermatology

Abstract:Summary Background and Objectives This study analyzed the extent to which the recent introduction of more effective treatments has led to an improvement in real‐world psoriasis patients. Patients and Methods Patient characteristics and the first‐year treatment effectiveness in biologic‐naive patients have been analyzed since 2004 until now, irrespective of treatment switches. Results Data from 2,729 patients were eligible for this analysis. The proportion of female patients increased significantly over the years from 29.9% to 36.2% (p < 0.028), while the number of patients with psoriatic arthritis declined from 36.6% to 30.0% (p < 0.001). Moreover, the duration of psoriatic disease and PASI at the start of the treatment significantly decreased. Last observation carrief forward (LOCF) analysis indicated that PASI 90 response increased from 18.9 to 44.6% at 3 months and from 32.9 to 66.8% at 12 months after treatment started. Similary, the PASI ≤ 3 rates increased from 33.2% to 66.0% at 3 months and from 41.9% to 78.9% at 12 months after the treatment started. Conclusions The continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes. Though one out of three to five patients, depending on the endpoint selected, nowadays still does not achieve an entirely satisfactory treatment response (i.e., PASI 90 or PASI ≤ 3).
Psoriasis treatment and biologic switching: The association with clinical characteristics and laboratory biomarkers over a 13‐year retrospective study

Asumi Koyama,Lixin Li,Toyoki Yamamoto,Haruka Taira,Eiki Sugimoto,Yukiko Ito,Yuka Mizuno,Kentaro Awaji,Shoko Tateishi,Hiroko Kanda,Shinichi Sato,Sayaka Shibata

DOI: https://doi.org/10.1111/1346-8138.17465

IF: 3.468

2024-09-15

The Journal of Dermatology

Abstract:The advent of biologics has greatly improved patient outcomes, yet some patients are compelled to switch therapies. Predicting these therapeutic failures is important; however, the factors associated with switching biologics have not been fully explored. This study examined patterns and determinants of biologics switching in psoriasis treatment retrospectively over 13 years. We focused on the association between clinical characteristics, basal laboratory data, and frequency of biologics switching. The findings revealed that elevated Psoriasis Area Severity Index scores and the presence of arthritis were observed in patients who experienced two or more treatment switches compared with those without treatment switches. Moreover, neutrophil to lymphocyte ratio was associated with higher biologics switching rates, indicating that systemic inflammation significantly impacts treatment adherence. A treatment approach, taking into account both the clinical presentation and inflammatory biomarkers, may be important for optimizing patient management in psoriasis.

dermatology
A High Level of Clinical Response is Associated with Improved Patient‐reported Outcomes in Psoriasis: Analyses from a Phase 2 Study in Patients Treated with Ixekizumab

Emily Edson‐Heredia,Subhashis Banerjee,Baojin Zhu,Tomoko Maeda‐Chubachi,Gregory S. Cameron,Wei Shen,Michael Heffernan,Kenneth B. Gordon,Craig L. Leonardi

DOI: https://doi.org/10.1111/jdv.13032

2015-01-01

Abstract:Journal of the European Academy of Dermatology and VenereologyVolume 30, Issue 5 p. 864-865 Letter to the Editor A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab E. Edson-Heredia, E. Edson-Heredia Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorS. Banerjee, S. Banerjee Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorB. Zhu, B. Zhu Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorT. Maeda-Chubachi, T. Maeda-Chubachi Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorG.S. Cameron, G.S. Cameron Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorW. Shen, W. Shen Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorM.P. Heffernan, M.P. Heffernan Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorK.B. Gordon, K.B. Gordon Feinberg School of Medicine, Northwestern University, Chicago, IL, USASearch for more papers by this authorC.L. Leonardi, Corresponding Author C.L. Leonardi St. Louis University School of Medicine, St. Louis, MO, USACorrespondence: C.L. Leonardi. E-mail: [email protected]Search for more papers by this author E. Edson-Heredia, E. Edson-Heredia Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorS. Banerjee, S. Banerjee Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorB. Zhu, B. Zhu Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorT. Maeda-Chubachi, T. Maeda-Chubachi Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorG.S. Cameron, G.S. Cameron Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorW. Shen, W. Shen Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorM.P. Heffernan, M.P. Heffernan Eli Lilly and Company, Indianapolis, IN, USASearch for more papers by this authorK.B. Gordon, K.B. Gordon Feinberg School of Medicine, Northwestern University, Chicago, IL, USASearch for more papers by this authorC.L. Leonardi, Corresponding Author C.L. Leonardi St. Louis University School of Medicine, St. Louis, MO, USACorrespondence: C.L. Leonardi. E-mail: [email protected]Search for more papers by this author First published: 13 March 2015 https://doi.org/10.1111/jdv.13032Citations: 23Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 European Medicines Agency Committee for Medicinal Products for Human Use. 2004. Guideline on Clinical Investigation of Medicinal Products for the Treatment of Psoriasis. CHMP/EWP/2454/02 corr. [WWW document] URL http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf (last accessed 17 January 2014). 2Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and Psoriatic arthritis. J Am Acad Dermatol 2008; 58: 826–850. 3Feldman SR, Kreuger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64(Suppl. 2): ii65–ii68. 4Revicki DA, Willian MK, Menter A et al. Relationship between clinical response to therapy and health-related quality of life in patients with moderate to severe plaque psoriasis. Dermatology 2008; 216: 260–270. 5Shikiar R, Bresnahan BW, Stone SP et al. Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1: 53. 6Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004; 150: 317–326. 7Shikiar R, Willian MK, Okun MM et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71. 8Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190–1199. Citing Literature Volume30, Issue5May 2016Pages 864-865 ReferencesRelatedInformation
Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of pasi score

Husein Husein-ElAhmed,Sara Husein-ElAhmed

DOI: https://doi.org/10.1093/ced/llae131

2024-04-15

Abstract:Background: Psoriasis is a chronic skin condition, for which the approval of several biologics has made a dramatic impact. Despite their initial treatment effectiveness, the challenge lies in understanding the long-term responses, as they may diminish over time. Limitations of the drug survival analysis warrant the application of additional outcomes to fully capture the performance of a biologic. We aimed to provide a broader perspective on the global landscape of biologic agents' persistence in positive clinical response by comparing innovative therapies over a 5-year period through a systematic review and network meta-analysis (NMA). Methods: We comprehensively identified studies in Pubmed, EMBASE, Scopus and clinicaltrial.gov. We defined two outcomes: 1) "persistence at optimal response" (POR) or "clinical remission", and 2) "persistence at suboptimal response" (PSR) or "low disease activity" as the proportion of patients with continuous exposition to a biologic who achieved a PASI 100 or PASI 90 responses, respectively, at the end of the predefined 5-year follow-up period. Results: Eleven publications, comprising 18 RCTs and 11,202 patients met inclusion criteria and were included in the NMA. In the ranking analysis, guselkumab exhibited the highest cumulative (0.8397250), followed by ixekizumab (0.8185545), and risankizumab (0.7643864). Conversely, etanercept (0.4152295), brodalumab (0.3633977), apremilast (0.2452136), and placebo (0.0263) showed the lowest cumulative probability of POR. For PSR, guselkumab (0.86083636), ixekizumab (0.74931136), and risankizumab (0.71293182) also held the top ranks, while brodalumab (0.41740227), secukinumab (0.231575), etanercept (0.192775), and placebo (0.01934545) presented the lowest PSR probabilities. Conclusion: The highest rates of persistence with clear or almost clear skin can be expected with guselkumab, ixekizumab and risankizumab compared to other biologics. The proposed proxy definitions of long-term persistence (POR and PSR) are reliable measures of patients being successfully treated that warrant further exploration and validation.
Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004-2023)

Yingdong Wang,Junchen Li,Chenqi Guo,Guojing Yang,Haiyue Lin,Yu Zhang

DOI: https://doi.org/10.1080/09546634.2024.2346282

Abstract:Background: Biologics are essential in treating psoriasis. In recent years, the pathogenesis exploration and development of new target drugs have provided a more complete evidence-based foundation for the biological treatment of psoriasis. This study aims to use bibliometrics to analyze the research status and development trends of biologics in psoriasis. Methods: The bibliometric analysis of publications related to biologics in psoriasis from 2004 to 2023 was conducted using the Web of Science Core Collection (WoSCC) database as the search data source. To perform the bibliometric analysis and create visual knowledge graphs, CiteSpace, the Bibliometrix R package, and VOSviewers were utilized. Results: The study included a total of 3800 articles. The United States had the highest number of publications. The leading authors and institutions were Steven R. Feldman and the University of Manchester, respectively, in the global partnership. The cluster plot divided all keywords into 11 categories. Currently, Secukinumab and Guselkumab are representative biological agents being studied due to their considerable efficacy and long-term safety. Conclusions: Targeted therapy has emerged as a significant trend in the current treatment of psoriasis. Early and active use of biologics can effectively control disease progression, prevent or delay the occurrence of comorbidities, and may even alter the natural course of psoriasis. However, further investigation is required to fully understand the specific mechanisms of psoriasis and the use of biological agents.
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

Andreas Pinter,Kilian Eyerich,Antonio Costanzo,Alyssa Garrelts,Christopher Schuster,Can Mert,Anastasia Lampropoulou,Konstantinos Fotiou,Julia-Tatjana Maul,Kim A. Papp

DOI: https://doi.org/10.1080/09546634.2024.2350227

2024-05-28

Journal of Dermatological Treatment

Abstract:Purpose Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this post-hoc analysis, using real world data from the Psoriasis Study of Health Outcomes (PSoHO), is to provide evidence if early intervention with biologics is associated with better treatment outcomes and if there is any difference among drug classes or individual biologics.

dermatology
Factors Associated With Achieving Complete Skin Clearance Compared to Almost Complete Skin Clearance in Patients With Moderate to Severe Psoriasis Treated With Biologics: A Retrospective Chart Review

Eun Ji Hong,Hee Jung Yoon,Min Jung Kwon,Jae Yun Kim,Jung Eun Kim,Young Lip Park,SangHoon Lee,Youin Bae,Sul Hee Lee

DOI: https://doi.org/10.5021/ad.23.074

2024-01-01

Annals of Dermatology

Abstract:BACKGROUND: Biologics have demonstrated high efficacy in achieving 'almost complete' skin clearance in patients with moderate to severe psoriasis. Nonetheless, achieving 'complete' skin clearance remains a treatment goal for some highly biologics-resistant patients, as residual lesions impact their quality of life.OBJECTIVE: The risk factors for failure to achieve a Psoriasis Area and Severity Index (PASI) 100 response in patients with good response to biologics remain unknown.METHODS: This retrospective study evaluated the risk factors by comparing patients who achieved complete skin clearance (PASI100) with those who achieved almost complete skin clearance (PASI90). A database of 131 psoriasis patients treated with biologics, who achieved a PASI90 or PASI100 response, was reviewed from a tertiary referral hospital in South Korea. The patients were classified into PASI90 and PASI100 groups according to their PASI response.RESULTS: The PASI100 group had a lower prevalence of smoking history (adjusted odds ratio [OR], 0.34; 95% confidence interval [CI], 0.14-0.85; <i>p</i>=0.021) and psoriasis on the anterior lower legs at baseline (adjusted OR, 0.18; 95% CI, 0.03-0.99; <i>p</i>=0.049) than patients in the PASI90 group.CONCLUSION: This study suggested that smoking history and psoriatic skin lesions on the anterior lower legs are considered as the risk factors for the failure to achieve a PASI100 response in psoriasis patients treated with biologics.

dermatology
Clinical characteristics and outcomes of patients with COVID‐19 and psoriasis

Yu Meng,Furong Zeng,Huiyan Sun,Yayun Li,Xiang Chen,Guangtong Deng

DOI: https://doi.org/10.1002/jmv.28085

IF: 20.693

2022-08-27

Journal of Medical Virology

Abstract:ObjectivesTo summarize the clinical characteristics and explore the role of treatment types in outcomes among psoriasis patients with Coronavirus Disease 2019 (COVID‐19).MethodsThe principal summary measures used were pooled prevalence and risk ratio (RR) with 95% confidential interval (CI). R statistic software was used for all the analysis.ResultsA total of 19 studies including 4073 psoriasis patients with COVID‐19 were eligible for the meta‐analysis. The overall hospitalization rate is about 20.2% (95% CI, 12.7% ‐ 28.7%), and changed to be 18.0 (95% CI, 9.9% ‐ 27.6%) or 14.1 (95% CI, 5.9% ‐ 24.6%) after systemic or biologic treatment. Moreover, the overall fatality rate is 1.5% (95% CI, 0.4% ‐ 3.0%), and turned to be 0.7 (95% CI, 0 ‐ 2.0%) or 0.5 (95% CI, 0 ‐ 2.2%) after systemic or biologic therapy. Notably, a lower hospitalization risk ratio was found in patients receiving biologic therapy than those receiving other treatments (RR = 0.62, 95%CI, 0.42‐0.94). The results were consistent after sensitivity analysis and trim‐and‐fill analysis.ConclusionsSystemic, especially biologic therapy could lessen the clinical severity in psoriasis patients with COVID‐19. Our finding will help to guide current recommendations and provide a reference for clinical decision‐making.This article is protected by copyright. All rights reserved.

virology

Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study

Characteristics of Patients With Psoriasis Treated With Various Biologics - A Danish Cohort Study

Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials

Mechanisms in residual plaques in patients with an overall good response to biologics

HLA‐C*06:02 in Danish patients with psoriasis and response to biological treatment

Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)

Chinese Experts Consensus on Biologic Therapy for Psoriasis #

Biomarkers of systemic treatment response in people with psoriasis: a scoping review

The impacts of biologic treatment on metabolic profiling in psoriasis

Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis

Association between several immune response‐related genes and the effectiveness of biological treatments in patients with moderate‐to‐severe psoriasis

Early Clinical Response As A Predictor of Subsequent Response to Ixekizumab Treatment: Results from A Phase Ii Study of Patients with Moderate-To-Severe Plaque Psoriasis

Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004–2022

Psoriasis treatment and biologic switching: The association with clinical characteristics and laboratory biomarkers over a 13‐year retrospective study

A High Level of Clinical Response is Associated with Improved Patient‐reported Outcomes in Psoriasis: Analyses from a Phase 2 Study in Patients Treated with Ixekizumab

Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of pasi score

Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004-2023)

Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

Factors Associated With Achieving Complete Skin Clearance Compared to Almost Complete Skin Clearance in Patients With Moderate to Severe Psoriasis Treated With Biologics: A Retrospective Chart Review

Clinical characteristics and outcomes of patients with COVID‐19 and psoriasis